NA 1

Drug Profile

NA 1

Alternative Names: NA-1; Tat-NR2B9c

Latest Information Update: 31 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arbor Vita Corporation; NoNO
  • Class Peptides; Vascular disorder therapies
  • Mechanism of Action PDZ domain inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Stroke

Most Recent Events

  • 31 Aug 2018 NA 1 is still in phase III trials for Stroke in Canada
  • 27 Feb 2017 NoNO initiates enrolment in the phase III ESCAPE-NA1 trial for Stroke in Canada (NCT02930018)
  • 14 Oct 2016 NoNO Inc. plans a phase III trial for Stroke in Canada (NCT02930018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top